Joanne Bowen
Overview
Explore the profile of Joanne Bowen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1156
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bellas O, Cao K, Bowen J, Smid S, Shakib S, Crawford G, et al.
BMJ Open
. 2025 Mar;
15(3):e089336.
PMID: 40032389
Introduction: Many chemotherapy agents used to treat advanced cancer are inherently mucotoxic, causing breakdown of the gastrointestinal mucosa (gastrointestinal mucositis (GI-M)) and lead to a constellation of secondary complications including...
2.
White C, Wardill H, Paul C, Price T, Karapetis C, Nalder M, et al.
BMC Cancer
. 2024 Nov;
24(1):1369.
PMID: 39516829
Background: Fluoropyrimidine (FP) chemotherapies are commonly prescribed for upper and lower gastrointestinal, breast and head and neck malignancies. Over 16,000 people with cancer require FP chemotherapies per annum in Australia....
3.
Chan R, Knowles R, Ashbury F, Bowen J, Chan A, Chin M, et al.
EClinicalMedicine
. 2024 Sep;
76:102825.
PMID: 39309723
Background: Supportive care to ensure optimal quality of life is an essential component of cancer care and symptom control across the lifespan. Ongoing advances in cancer treatment, increasing toxicity from...
4.
Bowen J, Braga S, Zotto V, Finnie J, DiPrimeo D, Cooke B, et al.
Physiol Rep
. 2024 Aug;
12(16):e70008.
PMID: 39187401
The irreversible pan-HER tyrosine kinase inhibitor neratinib is approved for patients with HER2-positive, early-stage and metastatic breast cancer (BC). Neratinib-associated diarrhea is the most common reason for early discontinuation. Preclinical...
5.
Bowen J, Cross C
Int J Mol Sci
. 2023 Nov;
24(22).
PMID: 38003503
Oral mucositis (OM) is a significant complication of cancer therapy with limited management strategies. Whilst inflammation is a central feature of destructive and ultimately ulcerative pathology, to date, attempts to...
6.
Cross C, Davies M, Bateman E, Crame E, Joyce P, Wignall A, et al.
Brain Behav Immun
. 2023 Sep;
115:13-25.
PMID: 37757978
The gastrointestinal microbiota has received increasing recognition as a key mediator of neurological conditions with neuroinflammatory features, through its production of the bioactive metabolites, short-chain fatty acids (SCFAs). Although neuroinflammation...
7.
Al-Qadami G, Bowen J, Van Sebille Y, Secombe K, Dorraki M, Verjans J, et al.
Support Care Cancer
. 2023 Jan;
31(1):98.
PMID: 36607434
Purpose: Mounting evidence suggests that the gut microbiome influences radiotherapy efficacy and toxicity by modulating immune signalling. However, its contribution to radiotherapy outcomes in head and neck cancer (HNC) is...
8.
Harata-Lee Y, Qu Z, Bateman E, Xiao X, Keller M, Bowen J, et al.
Front Oncol
. 2022 Aug;
12:929735.
PMID: 36033515
Mucositis, or damage/injury to mucous membranes of the alimentary, respiratory, or genitourinary tract, is the major side effect associated with anticancer radiotherapies. Because there is no effective treatment for mucositis...
9.
Raja Sharin R, Khan J, Johari Ibahim M, Muhamad M, Bowen J, Wan Mohamad Zain W
Biomed Res Int
. 2022 Jul;
2022:4165808.
PMID: 35800225
Lapatinib, an orally administered small-molecule tyrosine kinase inhibitor (SM-TKI), is an effective treatment for ErbB2-positive breast cancer. However, its efficacy as one of the targeted cancer therapies has been hampered...
10.
Al-Qadami G, Van Sebille Y, Bowen J, Wardill H
Front Oral Health
. 2022 Apr;
3:881949.
PMID: 35419563
Oral mucositis (OM) is one of the most common and debilitating oral complications of cancer treatments including chemotherapy, radiotherapy, and hematopoietic stem cell transplantation. It is associated with severe pain...